NeoGenomics Announces Leadership Changes and Compensatory Arrangements
Ticker: NEO · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1077183
Sentiment: neutral
Topics: leadership-change, executive-compensation, cmo-appointment
Related Tickers: NEO
TL;DR
NeoGenomics swapped a director and named a new CMO, with new pay details for execs.
AI Summary
On January 14, 2025, NeoGenomics, Inc. announced the departure of Director Dr. Jonathan R. Rothberg and the appointment of Dr. David M. Goldenberg as Chief Medical Officer. The company also disclosed compensatory arrangements for certain officers, details of which are provided in the filing.
Why It Matters
Changes in key leadership roles like Chief Medical Officer can signal shifts in the company's strategic direction and focus on medical affairs.
Risk Assessment
Risk Level: medium — Leadership changes and executive compensation disclosures can sometimes indicate underlying company performance or strategic shifts that may impact future results.
Key Players & Entities
- NeoGenomics, Inc. (company) — Registrant
- Dr. Jonathan R. Rothberg (person) — Departing Director
- Dr. David M. Goldenberg (person) — Appointed Chief Medical Officer
FAQ
Who has departed from NeoGenomics' board of directors?
Dr. Jonathan R. Rothberg has departed from NeoGenomics' board of directors as of January 14, 2025.
Who has been appointed as the new Chief Medical Officer?
Dr. David M. Goldenberg has been appointed as the Chief Medical Officer.
What is the effective date of these reported events?
The earliest event reported is dated January 14, 2025.
What other information is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements of certain officers.
What is NeoGenomics, Inc.'s state of incorporation and fiscal year end?
NeoGenomics, Inc. is incorporated in Nevada and its fiscal year ends on December 31.
Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2025-01-15 07:26:54
Key Financial Figures
- $0.001 — ange on which registered Common stock ($0.001 par value) NEO The Nasdaq Stock Market
- $400,000 — Bonus was comprised of a cash bonus of $400,000, which will be payable on April 13, 202
- $750,000 — e remains employed as of such date, and $750,000 of restricted stock units ("RSUs") that
Filing Documents
- neo-20250114.htm (8-K) — 34KB
- neogenomicsprovides2025f.htm (EX-99.1) — 7KB
- neogenomicsprovides2025f001.jpg (GRAPHIC) — 192KB
- neogenomicsprovides2025f002.jpg (GRAPHIC) — 228KB
- 0001077183-25-000007.txt ( ) — 745KB
- neo-20250114.xsd (EX-101.SCH) — 2KB
- neo-20250114_lab.xml (EX-101.LAB) — 22KB
- neo-20250114_pre.xml (EX-101.PRE) — 13KB
- neo-20250114_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 15, 2025, the Company issued a press release describing its long range plan and 2025 earnings guidance, the entire text of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and herein are deemed to be furnished and shall not be deemed to be filed.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 99.1 Press Release of NeoGenomics, Inc., dated January 1 5 , 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: January 10, 2025 By: /s/ Jeffrey S. Sherman Name: Jeffrey S. Sherman Title: Chief Financial Officer